论著

三种不同品牌ELISA试剂盒检测ASCA的结果比较及性能评估

展开
  • 上海交通大学医学院附属新华医院检验科,上海 200092

收稿日期: 2018-11-01

  网络出版日期: 2019-08-25

基金资助

上海市科学技术委员会科研计划项目(15DZ1940800);上海市卫生局课题(20154Y0095)

Comparison of results and evaluation of performance of three different ELISA kits for detection of ASCA

Expand
  • Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received date: 2018-11-01

  Online published: 2019-08-25

摘要

目的: 比较3种品牌酶联免疫吸附试验(enzyme-linked immunosorbent assay, ELISA)试剂盒检测血清抗酿酒酵母菌抗体(anti-saccharomyces cerevisiae antibodies, ASCA)的结果,分析一致性情况,并评估各试剂盒的主要检测性能,为临床使用提供参考。方法: 收集本院确诊炎症性肠病(inflammatory bowel disease,IBD)患者140例,其中克罗恩病(Crohn’s disease,CD)87例和溃疡性结肠炎(ulcerativecolitis, UC)53例,疾病对照组(disease contorl,DC)40例。用3个品牌的ELISA试剂盒(试剂盒A为国产品牌、B和C为进口品牌)分别检测ASCA-IgA和ASCA-IgG,对结果进行比较分析。结果: CD组中3个品牌试剂盒ASCA-IgA和(或)ASCA-IgG的检出率均高于UC组及DC组(P<0.05),而UC组与DC组间结果差异无统计学意义(P>0.05)。在UC组和DC组间,3种试剂的阳性检出率间差异无统计学意义(P>0.05);在CD组中,试剂盒A与B的阳性检出率间差异无统计学意义(P>0.05),而试剂盒C的结果低于试剂盒A、B,差异有统计学意义(P<0.05)。3种试剂检测结果的一致性分析显示,ASCA-IgA中,试剂盒A与B呈现中等一致性(Kappa:0.423),试剂盒A与C、试剂盒B与C的一致性较差(Kappa分别为0.111和0.074);ASCA-IgG中,试剂盒A与B、试剂盒B与C及试剂盒A与C均呈现中等一致性(Kappa分别为0.414、0.447和0.584)。评估3种ELISA试剂盒分别检测ASCA-IgA、ASCA-IgG及联合检测ASCA-IgA和ASCA-IgG诊断IBD的效能,试剂盒A灵敏度依次为37.90%、27.86%、43.57%,试剂盒B为20.71%、45.00%、51.43%,试剂盒C为9.29%、22.14%、25.71%;试剂盒A特异度依次为87.50%、85.00%、77.50%,试剂盒B为92.50%、90.00%、87.50%,试剂盒C为97.50%、90.00%、87.50%;试剂盒A约登指数分别为0.25、0.12、0.21,试剂盒B为0.13、0.35、0.38,试剂盒C为0.07、0.12、0.13;经受试者工作特征(receiver operating characteristic,ROC)曲线得出曲线下面积,试剂盒A分别为0.72、0.54、0.59,试剂盒B为0.54、0.72、0.69,试剂盒C为0.64、0.52、0.57。结论: 3种试剂盒在CD组均具有较高的ASCA检出率,说明ELISA检测ASCA对于CD的诊断和鉴别诊断具有一定应用价值。不同试剂间的检测结果一致性尚不理想,3种试剂ASCA-IgG检测结果一致性总体优于ASCA-IgA结果。3种试剂灵敏度均较低,不适合作为人群的IBD筛查指标,同时检测IgG和IgA抗体可提高检测灵敏度。检测性能试剂B>A>C,进口试剂不一定优于国产试剂,可根据实际情况合理选择试剂。

本文引用格式

余悠悠, 曾俊祥, 罗婷, 邓琳, 潘秀军 . 三种不同品牌ELISA试剂盒检测ASCA的结果比较及性能评估[J]. 诊断学理论与实践, 2019 , 18(04) : 454 -459 . DOI: 10.16150/j.1671-2870.2019.04.014

Abstract

Objective: To compare the results of three brands of ELISA (enzyme-linked immunosorbent assay) kits for detection of serum anti-Saccharomyces cerevisiae antibody ASCA)and to evaluate the performance of each kit for clinical reference. Methods: One hundred and forty patients with inflammatory bowel disease (IBD) were enrolled, including 53 patients with ulcerative colitis (UC), 87 patients with Crohn'sdisease (CD); and 40 other patients were served as disease control group (DC). Three ELISA kits (kid A is a domestic brand, B and C are imported brands) were used to detect ASCA-IgA and ASCA-IgG, and the results were analyzed and compared. Results: The detection rates of ASCA-IgA and/or ASCA-IgG in CD group were higher than those in UC group and DC group (P<0.05), but there was no significant difference between UC group and DC group (P>0.05). In UC group and DC group, the positive rates of three kits had no significant difference (P>0.05); in CD group, the positive rates of kit A and B had no significant difference (P>0.05), but the result of kit C was lower than that of kit A and B (P<0.05). The results of consistency analysis showed that kits A and B had moderate consistency in detecting ASCA-IgA (Kappa: 0.423), kits A and C, kits B and C showed poor consistency (Kappa: 0.111 and 0.074, respectively); kits A and B, kits B and C and kits A and C showed moderate consistency in detecting ASCA-IgG (Kappa: 0.414, 0.447 and 0.584, respectively). The analytical performance of detecting ASCA-IgA, ASCA-IgG by three ELISA kits separately and jointly for the diagnosis of IBD showed that the sensitivity was kit A (37.90%, 27.86%, 43.57%), kit B (20.71%, 45.00%, 51.43%), kit C (9.29%, 22.14%, 25.71%); specificity was kit A (87.5%, 85.00%, 77.50%), kit B (92.50%, 90.00%, 87.50%) and kit C (97.5%, 90.0%, 87.50%). The Youden index was kit A (0.25, 0.12, 0.21), kit B (0.13, 0.35, 0.38), kit C (0.07, 0.12, 0.13). The AUC area obtained by receiver operating characteristic (ROC) curve were kit A(0.72, 0.54, 0.59), kit B (0.54, 0.72, 0.69), kit C (0.64, 0.52, 0.57). Conclusions: All the three kits had high positive rate in CD group, It showed that ELISA detection of ASCA has certain application value for the diagnosis and differential diagnosis of CD. The consistency of test results of different kits was not satisfactory, the consistency of the results of ASCA-IgG was better than that of ASCA-IgA. All three kits have low sensitivity and are not suitable for IBD screening of the population. Detecting ASCA-IgG and ASCA-IgA antibodies simultaneously could improve the detection sensitivity. Test performance showes kit B > A >C. The imported kit is not necessarily superior to the domestic kit, and the brand of kit should be selected according to the actual situation.

参考文献

[1] Ouyang Q, Xue LY. Inflammatory bowel disease in the 21(st) century in China: turning challenges into opportunities[J]. J Dig Dis. 2012 Apr; 13(4):195-199.
[2] Ooi CJ, Fock KM, Makharia GK, et al. The Asia-Pacific consensus on ulcerative colitis[J]. J Gastroenterol Hepatol, 2010, 25(3):453-468.
[3] Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease[J]. Annu Rev Immunol, 2010, 28:573-621.
[4] Mokrowiecka A, Gasiorowska A, Malecka-Panas E. pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease[J]. Hepatogastroenterology, 2007, 54(77):1443-1448.
[5] Bernstein CN, Eliakim A, Fedail S, et al. World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015[J]. J Clin Gastroenterol, 2016, 50(10):803-818.
[6] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2012年,广州)[J]. 中华内科杂志, 2012, 51(10):818-831.
[7] 曾俊祥, 罗婷, 葛文松, 等. 抗GP2和抗CUZD1抗体对克罗恩病的诊断价值评估[J]. 诊断学理论与实践, 2018, 17(4):433-438.
[8] 夏邦世, 吴金华. Kappa一致性检验在检验医学研究中的应用[J]. 中华检验医学杂志, 2006, 29(1):83-84.
[9] 冯茜. Logistic回归和ROC曲线综合评价四种指标对原发性肝癌的诊断价值[J]. 标记免疫分析与临床, 2016, 23(6):641-644.
[10] Zhou G, Song Y, Yang W, et al. ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease?[J]. Dig Dis, 2016, 34(1-2):90-97.
[11] Soubières AA, Poullis A. Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Disea-ses[J]. Inflamm Bowel Dis, 2016, 22(8):2016-2022.
[12] 曾俊祥, 潘秀军, 沈立松. 炎症性肠病血清学标志物的研究进展[J]. 检验医学, 2018, 33(2):170-176.
[13] Norouzinia M, Chaleshi V, Alizadeh AHM, et al. Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment[J]. Gastroenterol Hepa-tol Bed Bench, 2017, 10(3):155-167.
[14] Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease[J]. Gastroenterology, 2001, 120(4):827-833.
[15] Herszényi L, Tulassay Z. The role of autoantibodies in inflammatory bowel disease[J]. Dig Dis, 2012, 30(2):201-207.
[16] 张蜀澜, 李永哲, 李磊, 等. 联合检测炎症性肠病患者抗酿酒酵母细胞抗体和抗中性粒细胞抗体的临床意义[J]. 中华检验医学杂志, 2008, 31(10):1142-1146.
[17] 高翔, 胡品津, 郑瑶, 等. 炎症性肠病患者血清中自身抗体检测的临床意义[J]. 中华内科杂志, 2005, 44(6):428-430.
[18] 袁柏思, 金鑫鑫, 路又可, 等. 检测6种血清学抗体在120例炎症性肠病中的临床应用价值[J]. 中华消化杂志, 2015, 35(4):270-272.
[19] Ng SC, Hirai HW, Tsoi KK, et al. Systematic review with meta-analysis: accuracy of interferon-gamma releasing assay and anti-Saccharomyces cerevisiae antibody in differentiating intestinal tuberculosis from Crohn's disease in Asians[J]. J Gastroenterol Hepatol, 2014, 29(9):1664-1670.
文章导航

/